Yuyu Pharma: "Additional Advertising Opportunities Should Be Granted for Pharmaceuticals with Strong Scientific Evidence"

National Assembly Forum on "Measures to Revitalize Over-the-Counter Drugs Contributing to Public Health Promotion"

Yuyu Pharma announced on the 6th that it presented an agenda at a National Assembly forum, proposing that "additional advertising opportunities" should be granted when developing pharmaceuticals with a high level of scientific evidence.

Jang Jaewon, Head of Development and Sales at Yuyu Pharma, is presenting at the forum on "Measures to Revitalize Over-the-Counter Drugs Contributing to National Health Promotion," held on the 5th at the 3rd Seminar Room in the National Assembly Members' Office Building, Yeongdeungpo-gu, Seoul. Yuyu Pharma

The discussion forum titled "Measures to Revitalize Over-the-Counter Drugs Contributing to Public Health Promotion," hosted by Democratic Party lawmakers Lee Gaeho and Kim Yoon and organized by the Korean Pharmaceutical Association and the Health Consumer Network, was held the previous day at Seminar Room 3 in the National Assembly Members' Office Building, Yeongdeungpo-gu, Seoul. The session was chaired by former Ministry of Food and Drug Safety Commissioner Lee Eui-kyung, and featured presentations by Jae-won Jang, Head of Development and Sales at Yuyu Pharma; Kim Taegyu, Director of the Korean Pharmaceutical Association; Lee Chungwoo, Professor at Sookmyung Women's University; and Kim Heesun, Officer at the Ministry of Food and Drug Safety.

Jang delivered a presentation on the topic, "Granting Additional Advertising Opportunities for the Development of Pharmaceuticals with a High Level of Scientific Evidence." The main proposal was to allow advertising of "differentiated herbal formulation ingredient profiles" or "country of origin" only for products that reflect unknown physiologically active ingredients, in addition to the quality control marker substances, in order to enhance the efficacy of herbal medicines.

He also suggested that, in the case of equivalence tests required for over-the-counter drug approval (notification), when the minimum requirements are exceeded, this should be reflected in the approval details and advertising should be permitted. In this context, he cited Article 17 of the current pharmaceutical product approval review regulations, which pertains to "additional information for prescription drug professionals," and emphasized the need for "additional information for over-the-counter drugs."

Assemblyman Lee Gaeho stated, "I hope this forum will serve as an opportunity to seek ways to revitalize over-the-counter drugs that benefit pharmaceutical companies, pharmacies, and consumers alike," adding, "I hope over-the-counter drugs will become a new agenda for promoting public health."

Assemblyman Kim Yoon said, "A regular evaluation and discussion system should be established to reasonably switch prescription drugs with sufficiently verified safety and efficacy to over-the-counter status," and added, "Balanced policies are needed to ensure safe and rational drug use centered on the public, beyond the interests of specific groups."

This content was produced with the assistance of AI translation services.